DOUGLAS RICHARD purchased $129K of ALDX
DOUGLAS RICHARD purchased 200,000 shares of Aldeyra Therapeutics, Inc. (ALDX) at $0.64 ($0.13M total) on 2026-11-11.
How this was made
The 30-second read
Why it matters
The filing provides a concrete insider buy price and post-transaction holdings, but it does not disclose any new company event beyond the transaction itself.
Market read
Traders may treat this as a small sentiment input, but it is unlikely to drive a major repricing without accompanying fundamental news.
What to watch
Insider buying signals are more informative when paired with larger size, repeated buys, or concurrent fundamental catalysts; none are provided here.
Background
The article is a SEC Form 4 insider transaction disclosure for Aldeyra Therapeutics director Douglas Richard.
Ticker impact
A director at Aldeyra Therapeutics bought 200,000 shares open-market at $0.6445 on 2026-11-11, totaling about $128.9K.
Likely limited near-term impact, with any effect confined to sentiment and short-term positioning rather than fundamentals.
This is a Form 4 insider purchase with a clear transaction price and size, but it does not include new clinical, regulatory, or financial guidance.
Market effects
Minimal, as the disclosure is company-specific insider activity without sector-wide information.
None indicated.
None indicated.
Counterpoint
The purchase may be routine or driven by personal liquidity needs, and the article notes no pre-arranged 10b5-1 plan, which can still occur for non-informational reasons.
Key entities
- issuerAldeyra Therapeutics, Inc.
US-listed biotech subject of the Form 4 insider purchase disclosure.
- insiderDouglas Richard
Director who purchased 200,000 shares open-market.
